ABSTRACT

Introduction

Cutaneous leishmaniasis (CL), caused by different Leishmania parasite species, is associated with parasite-induced immune-mediated skin inflammation and ulceration. Whereas many CL studies focus on gene expression signatures in mouse models, the transcriptional response driving human patients in the field is less characterized. Human studies in CL disease provide the opportunity to directly investigate the host–pathogen interaction in the cutaneous lesion site.

Areas covered

Advances in high-throughput sequencing technologies, particularly their application for evaluation of the global gene expression changes, have made transcriptomics as a powerful tool to understand the pathogen-host molecular interactions.

Expert commentary

In this review, we focus on the transcriptomics studies that have been performed so far on human blood or tissue-driven samples to investigate Leishmania parasites interplay with the CL patients. Further, we summarize microarray and RNA-seq studies associated with lesion biopsies of CL patients to discuss how current whole genome analysis along with systems biology approaches have developed novel CL biomarkers for further applications, not only for research, but also for accelerating vaccine development.

中文翻译：

---

皮肤利什曼病患者的转录组学分析。

摘要

介绍

由不同的利什曼原虫物种引起的皮肤利什曼病 (CL)与寄生虫诱导的免疫介导的皮肤炎症和溃疡有关。尽管许多 CL 研究侧重于小鼠模型中的基因表达特征，但在该领域驱动人类患者的转录反应的特征较少。CL 疾病的人体研究提供了直接研究皮肤病变部位宿主-病原体相互作用的机会。

覆盖区域

高通量测序技术的进步，特别是它们在评估全球基因表达变化方面的应用，使转录组学成为了解病原体-宿主分子相互作用的有力工具。

专家评论

在这篇综述中，我们专注于迄今为止对人类血液或组织驱动样本进行的转录组学研究，以研究利什曼原虫寄生虫与 CL 患者的相互作用。此外，我们总结了与 CL 患者病变活检相关的微阵列和 RNA-seq 研究，以讨论当前的全基因组分析和系统生物学方法如何开发出新的 CL 生物标志物以供进一步应用，不仅用于研究，而且用于加速疫苗开发。